Protagonist Therapeutics Inc
PTGX85.400USD
+1.200+1.43%
收盘 11/21, 16:00（美东）报价延迟15分钟
5.29B总市值
10.01市盈率 TTM
关于 Protagonist Therapeutics Inc 公司
Protagonist Therapeutics, Inc. 是一家生物制药公司。该公司使用其肽基化学实体 rusfertide 和 JNJ-2113 进行不同的开发，这些实体均源自其专有的发现技术平台。该公司的临床项目分为两类疾病：血液学和血液疾病以及炎症和免疫调节疾病。其主要临床资产 rusfertide (PTG-300) 是一种可注射的铁调素类似物，正在开发中，用于治疗真性红细胞增多症 (PV) 和其他血液疾病。该公司的白细胞介素-23 受体 (IL-23R) 拮抗剂化合物 JNJ-2113 是一种口服的试验药物，旨在阻断已上市的可注射抗体药物所针对的生物途径。其 PN-943 是一种全资研究的口服肠道限制性 α4β7（α4β7）特异性整合素拮抗剂，用于治疗炎症性肠病（IBD）。
Protagonist Therapeutics Inc简介
公司代码PTGX
公司名称Protagonist Therapeutics Inc
上市日期Aug 11, 2016
CEODr. Dinesh V. Patel, Ph.D.
员工数量126
证券类型Ordinary Share
年结日Aug 11
公司地址7707 Gateway Blvd Ste 140
城市NEWARK
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编94560-1160
电话15104740170
网址https://www.protagonist-inc.com/
公司代码PTGX
上市日期Aug 11, 2016
CEODr. Dinesh V. Patel, Ph.D.
Protagonist Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
313.60K
-0.20%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
--
-100.00%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Mr. Corey Davis, Ph.D.
Mr. Corey Davis, Ph.D.
IR Contact Officer
IR Contact Officer
--
--
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
名称
名称/职务
职务
持股
持股变动
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
313.60K
-0.20%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+6.14%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
38.72K
+38.31%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
4.87K
-26.51%
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月19日 周三
更新时间: 11月19日 周三
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
12.83%
Farallon Capital Management, L.L.C.
9.91%
RTW Investments L.P.
9.21%
The Vanguard Group, Inc.
6.79%
State Street Investment Management (US)
5.06%
其他
56.19%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
12.83%
Farallon Capital Management, L.L.C.
9.91%
RTW Investments L.P.
9.21%
The Vanguard Group, Inc.
6.79%
State Street Investment Management (US)
5.06%
其他
56.19%
股东类型
持股股东
占比
Investment Advisor
38.79%
Investment Advisor/Hedge Fund
35.88%
Hedge Fund
27.18%
Research Firm
5.73%
Venture Capital
4.41%
Private Equity
1.74%
Pension Fund
1.09%
Individual Investor
1.01%
Bank and Trust
0.33%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
551
71.95M
115.09%
-3.63M
2025Q2
533
68.00M
109.30%
-9.94M
2025Q1
541
67.25M
108.51%
-8.96M
2024Q4
503
65.58M
106.87%
-12.21M
2024Q3
480
64.24M
108.98%
-11.36M
2024Q2
419
61.14M
104.21%
-15.61M
2024Q1
412
61.98M
106.36%
-12.46M
2023Q4
402
59.53M
103.21%
-16.02M
2023Q3
400
59.06M
102.70%
-14.36M
2023Q2
411
59.30M
103.68%
-17.88M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
8.46M
13.6%
-140.21K
-1.63%
Jun 30, 2025
Farallon Capital Management, L.L.C.
6.17M
9.92%
+65.00K
+1.06%
Jun 30, 2025
RTW Investments L.P.
5.76M
9.25%
+36.86K
+0.64%
Jun 30, 2025
The Vanguard Group, Inc.
4.35M
6.99%
+80.38K
+1.88%
Jun 30, 2025
State Street Investment Management (US)
3.21M
5.16%
+500.92K
+18.51%
Jun 30, 2025
BVF Partners L.P.
3.21M
5.16%
+636.03K
+24.70%
Jun 30, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.45M
3.94%
--
--
Jun 30, 2025
Wellington Management Company, LLP
1.04M
1.67%
+50.37K
+5.10%
Jun 30, 2025
UBS Financial Services, Inc.
2.50M
4.02%
+2.15M
+619.02%
Jun 30, 2025
Deep Track Capital LP
3.25M
5.22%
-4.10K
-0.13%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Invesco S&P SmallCap Health Care ETF
2.47%
ALPS Medical Breakthroughs ETF
2.39%
Invesco S&P SmallCap 600 Pure Growth ETF
2.24%
Invesco Dorsey Wright Healthcare Momentum ETF
2.13%
ETC 6 Meridian Small Cap Equity ETF
1.29%
SPDR S&P Biotech ETF
1.28%
Cambria Value and Momentum ETF
1%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Invesco S&P SmallCap Momentum ETF
0.77%
Direxion Daily S&P Biotech Bull 3X Shares
0.67%
查看更多
Invesco S&P SmallCap Health Care ETF
占比2.47%
ALPS Medical Breakthroughs ETF
占比2.39%
Invesco S&P SmallCap 600 Pure Growth ETF
占比2.24%
Invesco Dorsey Wright Healthcare Momentum ETF
占比2.13%
ETC 6 Meridian Small Cap Equity ETF
占比1.29%
SPDR S&P Biotech ETF
占比1.28%
Cambria Value and Momentum ETF
占比1%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.85%
Invesco S&P SmallCap Momentum ETF
占比0.77%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.67%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Protagonist Therapeutics Inc的前五大股东是谁？
Protagonist Therapeutics Inc 的前五大股东如下：
BlackRock Institutional Trust Company, N.A.持有股份：8.46M，占总股份比例：13.60%。
Farallon Capital Management, L.L.C.持有股份：6.17M，占总股份比例：9.92%。
RTW Investments L.P.持有股份：5.76M，占总股份比例：9.25%。
The Vanguard Group, Inc.持有股份：4.35M，占总股份比例：6.99%。
State Street Investment Management (US)持有股份：3.21M，占总股份比例：5.16%。
BlackRock Institutional Trust Company, N.A.持有股份：8.46M，占总股份比例：13.60%。
Farallon Capital Management, L.L.C.持有股份：6.17M，占总股份比例：9.92%。
RTW Investments L.P.持有股份：5.76M，占总股份比例：9.25%。
The Vanguard Group, Inc.持有股份：4.35M，占总股份比例：6.99%。
State Street Investment Management (US)持有股份：3.21M，占总股份比例：5.16%。
Protagonist Therapeutics Inc的前三大股东类型是什么？
Protagonist Therapeutics Inc 的前三大股东类型分别是：
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
RTW Investments L.P.
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
RTW Investments L.P.
有多少机构持有Protagonist Therapeutics Inc(PTGX)的股份？
截至2025Q3，共有551家机构持有Protagonist Therapeutics Inc的股份，合计持有的股份价值约为71.95M，占公司总股份的115.09%。与2025Q2相比，机构持股有所增加，增幅为5.78%。
哪个业务部门对Protagonist Therapeutics Inc的收入贡献最大？
在--，--业务部门对Protagonist Therapeutics Inc的收入贡献最大，创收--，占总收入的--%。
